Reading time ( words)
NOTE recently has entered an agreement with CellMark AB for the manufacture of a new medtech product, My+Care, a wristband that uses AI (artificial intelligence) to analyse and monitor user health. By capturing data, risks can be predicted, relatives and carers informed, thus preventing many injuries and accidents.
The contract has an estimated sales value of some SEK25 million in 2018. The scheduled production start is in the first quarter.
"Our medtech initiative remains successful. This is a great example of a complete solution, where, by bringing competence early in the process, we can support the customer so their product comes to market faster," said Per Ovrén, NOTE’s CEO and President.
"CellMark views NOTE as a long-term partner for developing and manufacturing medtech products, taking complete responsibility for testing, sourcing and manufacturing life-saving solutions, which fits CellMark's business model as a global platform for medtech entrepreneurs," responded Niclas Möttus-Olsson, President of CellMark Medical.